Enanta Pharmaceuticals, Inc. (FRA:9EP)

Germany flag Germany · Delayed Price · Currency is EUR
11.90
-0.10 (-0.83%)
Last updated: Dec 4, 2025, 7:55 PM CET
49.69%
Market Cap 362.23M
Revenue (ttm) 55.68M
Net Income (ttm) -69.79M
Shares Out n/a
EPS (ttm) -3.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 12.00
Previous Close 12.00
Day's Range 11.90 - 12.10
52-Week Range 3.62 - 12.60
Beta n/a
RSI 73.12
Earnings Date Nov 17, 2025

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the marke... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1995
Employees 120
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 9EP
Full Company Profile

Financial Performance

In 2025, Enanta Pharmaceuticals's revenue was $65.32 million, a decrease of -3.42% compared to the previous year's $67.64 million. Losses were -$81.89 million, -29.43% less than in 2024.

Financial numbers in USD Financial Statements

News

There is no news available yet.